EN HU
logo Tudóstér

Katona Éva

Katona Éva

Publication list

Tudóstér co-authors statistics filterable publication list
Uploaded publications:
92
Publications in DEA:
91
OA:
23
Date range:
1987-2024
2024
1.
Sang, Y., Lee, R. H., Luong, A., Katona, É., Whyte, C. S., Smith, N. L., Mast, A. E., Flick, M. J., Mutch, N. J., Bergmeier, W., Wolberg, A. S.: Activated platelets retain and protect most of their factor XIII-A cargo from proteolytic activation and degradation.
Blood Adv. 8 (19), 5072-5085, 2024.
doi DEA WoS Scopus
Journal metrics:
D1 Hematology (2023)
2.
Tóth, E. L., Orbán-Kálmándi, R. A., Bagoly, Z., Lóczi, L., Deli, T., Török, O., Deliné Molnár, S., Baráth, S., Singh, P., Hevessy, Z., Katona, É., Fagyas, M., Szabó, A. Á., Molnár, S., Krasznai, Z. T.: Case report: Complex evaluation of coagulation, fibrinolysis and inflammatory cytokines in a SARS-CoV-2 infected pregnant woman with fetal loss.
Front. Immunol. 15, 1-10, (article identifier: 1329236), 2024.
doi DEA WoS Scopus
Journal metrics:
Q1 Immunology (2023)
Q1 Immunology and Allergy (2023)
3.
Kállai, J., Gindele, R., Pénzes-Daku, K., Balogh, G., Kissné Bogáti, R., Bécsi, B., Katona, É., Oláh, Z., Ilonczai, P., Boda, Z., Róna-Tas, Á., Nemes, L., Marton, I., Bereczky, Z.: Clinical and Molecular Characterization of Nine Novel Antithrombin Mutations.
Int. J. Mol. Sci. 25 (5), 1-19, (article identifier: 2893), 2024.
doi DEA WoS Scopus
Journal metrics:
Q2 Catalysis (2023)
Q1 Computer Science Applications (2023)
D1 Inorganic Chemistry (2023)
Q1 Medicine (miscellaneous) (2023)
Q2 Molecular Biology (2023)
D1 Organic Chemistry (2023)
Q1 Physical and Theoretical Chemistry (2023)
D1 Spectroscopy (2023)
4.
Pituk, D., Balogh, L., Horváth, E., Hegyi, Z., Baráth, B., Kissné Bogáti, R., Szűcs, P., Papp, Z., Katona, É., Bereczky, Z.: Localization of Hemostasis Elements in Aspirated Coronary Thrombi at Different Stages of Evolution.
Int. J. Mol. Sci. 25 (21), 1-19, (article identifier: 11746), 2024.
doi DEA WoS Scopus
Journal metrics:
Q2 Catalysis (2023)
Q1 Computer Science Applications (2023)
D1 Inorganic Chemistry (2023)
Q1 Medicine (miscellaneous) (2023)
Q2 Molecular Biology (2023)
D1 Organic Chemistry (2023)
Q1 Physical and Theoretical Chemistry (2023)
D1 Spectroscopy (2023)
5.
Ghansah, H., Orbán-Kálmándi, R. A., Bekéné Debreceni, I., Katona, É., Rejtő, L., Váróczy, L., Lóczi, L., Laat, B. d., Huskens, D., Kappelmayer, J., Bagoly, Z.: Low factor XIII levels and altered fibrinolysis in patients with multiple myeloma.
Thromb. Res. 234, 12-20, 2024.
doi DEA WoS Scopus
Journal metrics:
Q1 Hematology (2023)
2023
6.
Somodi, L., Horváth, E., Bárdos, H., Baráth, B., Pethő, D., Katona, É., Balla, J., Mutch, N. J., Muszbek, L.: Cellular FXIII in Human Macrophage-Derived Foam Cells.
Int. J. Mol. Sci. 24 (5), 1-12, (article identifier: 4802), 2023.
doi DEA WoS Scopus
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
D1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
D1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
D1 Spectroscopy
7.
Katona, É.: Functional Consequences of Antibodies against Noncatalytic B Subunit of Factor XIII.
Thromb. Haemost. 123 (9), 855, 2023.
doi DEA WoS Scopus
2022
8.
Raut, S., Katona, É., Riches-Duit, A., Coxon, C., Muszbek, L., Schroeder, V., Rigsby, P.: An international collaborative study to assign value for Total Factor XIII-B Subunit Antigen to the WHO 1st International Standard for Factor XIII Plasma, (02/206): communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen.
J. Thromb. Haemost. 20 (2), 525-531, 2022.
doi DEA WoS Scopus
Journal metrics:
D1 Hematology
D1 Medicine (miscellaneous)
9.
Székely, E. G., Orbán-Kálmándi, R. A., Szegedi, I., Katona, É., Baráth, B., Czuriga-Kovács, K. R., Lóczi, L., Molnárné Vasas, N., Fekete, I., Fekete, K., Berényi, E., Oláh, L., Csiba, L., Bagoly, Z.: Low [alfa]2-Plasmin Inhibitor Antigen Levels on Admission Are Associated With More Severe Stroke and Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis.
Front. Cardiovasc. Med. 9, 1-14, 2022.
doi DEA WoS Scopus
Journal metrics:
Q1 Cardiology and Cardiovascular Medicine
10.
Kissné Bogáti, R., Katona, É., Shemirani, A. H., Balogh, E., Bárdos, H., Jeney, V., Muszbek, L.: The Effect of Activated FXIII, a Transglutaminase, on Vascular Smooth Muscle Cells.
Int. J. Mol. Sci. 23 (10), 1-15, 2022.
doi DEA WoS Scopus
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
D1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
Q1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
D1 Spectroscopy
2021
11.
Baráth, B., Kissné Bogáti, R., Miklós, T., Kállai, J., Mezei, Z. A., Bereczky, Z., Muszbek, L., Katona, É.: Effect of [alfa]2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism.
Thromb. Res. 203, 110-116, 2021.
doi DEA WoS Scopus
Journal metrics:
Q1 Hematology
12.
Plamenova, I., Zolkova, J., Sokol, J., Kolkova, Z., Bereczky, Z., Katona, É., Muszbek, L., Kubisz, P., Staško, J.: Genetic Background of Inherited Factor XIII-A Subunit Deficiency: review of the Literature and Description of Two New Cases.
Semin. Thromb. Hemost. 47 (7), 885-889, 2021.
doi DEA
Journal metrics:
Q1 Cardiology and Cardiovascular Medicine
Q1 Hematology
13.
Bagoly, Z., Baráth, B., Orbán-Kálmándi, R. A., Szegedi, I., Kissné Bogáti, R., Sarkady, F., Csiba, L., Katona, É.: Incorporation of [alfa]2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients.
Biomolecules. 11 (3), 1-13, 2021.
doi DEA WoS Scopus
Journal metrics:
Q2 Biochemistry
Q2 Molecular Biology
14.
Gindele, R., Pénzes-Daku, K., Balogh, G., Kállai, J., Kissné Bogáti, R., Bécsi, B., Erdődi, F., Katona, É., Bereczky, Z.: Investigation of the Differences in Antithrombin to Heparin Binding among Antithrombin Budapest 3, Basel, and Padua Mutations by Biochemical and In Silico Methods.
Biomolecules. 11 (4), 1-18, 2021.
doi DEA WoS Scopus
Journal metrics:
Q2 Biochemistry
Q2 Molecular Biology
15.
Potor, L., Hendrik, Z., Patsalos, A., Katona, É., Méhes, G., Póliska, S., Csősz, É., Kalló, G., Komáromi, I., Combi, Z., Posta, N., Sikura, K. É., Pethő, D., Oros, M., Vereb, G., Tóth, C., Gergely, P., Nagy, L., Balla, G., Balla, J.: Oxidation of hemoglobin drives a proatherogenic polarization of macrophages in human atherosclerosis.
Antioxid. Redox Signal. 35 (12), 917-950, 2021.
doi DEA WoS Scopus
Journal metrics:
D1 Biochemistry
Q1 Cell Biology
D1 Clinical Biochemistry
D1 Medicine (miscellaneous)
Q1 Molecular Biology
D1 Physiology
2020
16.
Bovet, J., Hurják, B., Maistre, E. D., Katona, É., Pénzes-Daku, K., Muszbek, L.: Autoimmune Factor XIII Deficiency With Unusual Laboratory and Clinical Phenotype.
J. Thromb. Haemost. 18 (6), 1330-1334, 2020.
doi DEA WoS Scopus
Journal metrics:
Q1 Hematology
D1 Medicine (miscellaneous)
17.
Hurják, B., Kovács, Z., Döncző, B., Katona, É., Haramura, G., Erdélyi, F., Shemirani, A. H., Sadeghi, F., Muszbek, L., Guttman, A.: N-glycosylation of blood coagulation factor XIII subunit B and its functional consequence.
J. Thromb. Haemost. 18 (6), 1302-1309, 2020.
doi DEA WoS Scopus
Journal metrics:
Q1 Hematology
D1 Medicine (miscellaneous)
18.
Ząbczyk, M., Natorska, J., Bagoly, Z., Sarkady, F., Baráth, B., Katona, É., Bryk, A. H., Zettl, K., Wisniewski, J. R., Undas, A.: Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
J. Physiol. Pharmacol. 71 (4), 519-524, 2020.
doi DEA
Journal metrics:
Q2 Medicine (miscellaneous)
Q2 Pharmacology
Q2 Physiology
19.
Bryk, A. H., Siudut, J., Broniatowska, E., Bagoly, Z., Baráth, B., Katona, É., Undas, A.: Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes.
Thromb. Res. 185, 88-62, 2020.
doi DEA WoS Scopus
Journal metrics:
Q1 Hematology
20.
Pénzes-Daku, K., Hurják, B., Katona, É., Becs, G., Balla, J., Muszbek, L.: Terminal Phase Components of the Clotting Cascade in Patients with End-Stage Renal Disease Undergoing Hemodiafiltration or Hemodialysis Treatment.
Int. J. Mol. Sci. 21, 1-15, 2020.
doi DEA WoS Scopus
Journal metrics:
Q2 Catalysis
D1 Computer Science Applications
D1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
D1 Organic Chemistry
D1 Physical and Theoretical Chemistry
D1 Spectroscopy
2019
21.
Orosz, A., Csapó, A., Bagoly, Z., Székely, E. G., Tóth, E., Kovács, B., Bereczky, Z., Muszbek, L., Katona, É.: A new ELISA method for the measurement of total α2-plasmin inhibitor level in human body fluids.
J. Immunol. Methods. 471, 27-33, 2019.
doi DEA Scopus
Journal metrics:
Q3 Immunology
Q2 Immunology and Allergy
2018
22.
Katona, É., Kissné Bogáti, R., Miklós, T., Gindele, R., Speker, M., Fedoriska, V., Orosz, A., Mezei, Z. A., Bereczky, Z.: ALPHA-2 Plasmin Inhibitor Activity and Antigen Levels and p.Arg6Trp Polymorphism in Patients with Venous Thromboembolism.
Proceedings. 2 (9), 102-103, 2018.
doi DEA
23.
Muszbek, L., Katona, É., Pénzes-Daku, K.: Antibodies against factor XIII subunits.
In: Factor XIII Clinical and Laboratory Aspects - ECAT Foundation. Eds.: Helena Laboratories, ECAT Foundation, Voorschoten, 17-21, 2017.
DEA
24.
Muszbek, L., Pénzes-Daku, K., Katona, É.: Auto-, and alloantibodies against factor XIII: laboratory diagnosis and clinical consequences.
J. Thromb. Haemost. 16 (5), 822-832, 2018.
doi DEA WoS Scopus
Journal metrics:
Q1 Hematology
D1 Medicine (miscellaneous)
25.
Balogh, L., Katona, É., Mezei, Z. A., Kállai, J., Gindele, R., Édes, I., Muszbek, L., Papp, Z., Bereczky, Z.: Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients.
Mol. Cell. Biochem. 448 (1-2), 199-209, 2018.
doi DEA
Journal metrics:
Q3 Cell Biology
Q2 Clinical Biochemistry
Q1 Medicine (miscellaneous)
Q3 Molecular Biology
DEENK University of Debrecen
© 2012 University of Debrecen
We use cookies on this site to enhance your user experience. By continuing to use the site, you agree to the use of cookies.